| Li, Li |
NCT06697522: Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children |
|
|
| Completed | 3 | 148 | RoW | Atropine Sulfate, Investigational product, Placebo, Blank Solvent | Ocumension Therapeutics (Suzhou) Co., Ltd, Beijing Children's Hospital | Myopia | 10/23 | 03/24 | | |
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults |
|
|
| Completed | 3 | 286 | RoW | Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis | Cutia Therapeutics（Wuxi）Co.,Ltd | Analgesia | 08/23 | 10/23 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
|
|
| Recruiting | 3 | 600 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | OSA, Overweight or Obesity | 11/26 | 01/27 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 140 | US | KB707, Opdualag | Krystal Biotech, Inc. | Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma | 07/26 | 07/26 | | |
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy |
|
|
| Recruiting | 1 | 40 | RoW | TQB2858 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cervical Cancer | 05/23 | 07/23 | | |
NCT06678581: SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects |
|
|
| Completed | 1 | 70 | RoW | SAP-001, SAP-001 tablet, Placebo, placebo tablet | Shanton Pharma Co., Ltd. | Gout, Hyperuricemia | 12/23 | 01/24 | | |
DEVIF-I, NCT06230822: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 1 | 9 | RoW | VUM02 Injection, Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Idiopathic Pulmonary Fibrosis | 01/25 | 12/26 | | |
OASIS, NCT06063317: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 33 | US | CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto | Imugene Limited | Solid Tumor, Adult | 06/27 | 05/29 | | |
| Lai, Yongrong |
NCT06302491: A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia |
|
|
| Recruiting | 2 | 64 | RoW | AND017 capsules, AND017 Placebo | Kind Pharmaceuticals LLC | β -Thalassemia | 12/25 | 07/26 | | |
NCT06465550: A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major |
|
|
| Recruiting | 1 | 9 | RoW | BD211 | Shanghai BDgene Co., Ltd. | β-thalassemia | 12/26 | 12/26 | | |
| Enrolling by invitation | 1 | 10 | RoW | CS-101 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 12/25 | 01/26 | | |
NCT06291961: A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major |
|
|
| Recruiting | 1 | 8 | RoW | CS-101 injection | CorrectSequence Therapeutics Co., Ltd | Beta-Thalassemia Major | 05/25 | 07/25 | | |
NCT06655662: Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients. |
|
|
| Recruiting | 1 | 8 | RoW | β-globin restored autologous hematopoietic stem cells | Shenzhen Hemogen | Β-thalassemia | 12/25 | 12/26 | | |
| Recruiting | 1 | 5 | RoW | CS-206 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Sickle Cell Disease | 12/26 | 06/27 | | |
NCT06772766: A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia |
|
|
| Recruiting | 1 | 40 | RoW | 9MW3011, 9MW3011 placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Beta-Thalassemia | 10/26 | 10/26 | | |
NCT06024876: A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia |
|
|
| Active, not recruiting | 1 | 5 | RoW | CS-101 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 12/24 | 06/25 | | |
NCT05577312: Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia |
|
|
| Enrolling by invitation | 1 | 9 | RoW | BRL-101, BRL-101 autologous hematopoietic stem and progenitor cells injection | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University | Beta-Thalassemia | 08/25 | 09/26 | | |
| Enrolling by invitation | N/A | 3 | RoW | BRL-101, Autologous hematopoietic stem and progenitor cells injection | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University | Sickle Cell Disease | 03/26 | 06/26 | | |
| Not yet recruiting | N/A | 45 | RoW | Assessments | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Shenzhen Children 's Hospital | Thalassemia, Beta | 08/38 | 10/38 | | |
NCT06685536: A Long-term Follow-up Study in Participants Who Received CS-101 |
|
|
| Enrolling by invitation | N/A | 5 | RoW | Safety and efficacy assessments | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 07/39 | 07/39 | | |
| Qin, Xiao |
NCT03683459: Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter |
|
|
| Recruiting | N/A | 208 | RoW | FemFlow Drug-Eluting Peripheral Balloon Catheter | Lifetech Scientific (Shenzhen) Co., Ltd. | Femoral Artery Stenosis, Femoral Artery Occlusion, Popliteal Arterial Stenosis, Popliteal Artery Occlusion | 12/22 | 12/22 | | |
GENIUS, NCT04849325: IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease |
|
|
| Recruiting | N/A | 120 | RoW | Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titanâ„¢), Percutaneous Transluminal Angioplasty (PTA) Device | Biotyx Medical (Shenzhen) Co., Ltd. | Critical Limb Ischemia (CLI) | 04/24 | 10/24 | | |
| Su, Minghua |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B |
|
|
| Not yet recruiting | 1/2 | 162 | RoW | TQA3038 injection/placebo, Nucleotide drugs Control group | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B, Chronic | 09/26 | 09/26 | | |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
| Peng, Zhigang |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Zheng, Jinou |
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 110 | Europe, Canada, US, RoW | Efgartigimod IV, Placebo IV | argenx | Generalized Myasthenia Gravis | 07/25 | 07/27 | | |
